Acasti Pharma Inc. (ACST) Sets 12-Month Low on Jun, 29

June 29, 2018 - By Michael Lund

Acasti Pharma Inc. (NASDAQ:ACST) Corporate Logo

Acasti Pharma Inc. (NASDAQ:ACST) touched 1-year low touching $0.64. Our target is $0.59. Barchart.com reported the 1-year low on Jun, 29. Acasti Pharma Inc. (NASDAQ:ACST) has $25.26 million MC. At our $0.59 target, the company worth will be $2.02M less.

Ticker’s shares touched $0.6397 during the last trading session after 1.88% change.Currently Acasti Pharma Inc. is downtrending after 43.65% change in last June 29, 2017. ACST has 42,057 shares volume. ACST underperformed by 56.22% the S&P500.

For more Acasti Pharma Inc. (NASDAQ:ACST) news posted recently go to: Benzinga.com, Nasdaq.com, Nasdaq.com, Globenewswire.com or Streetinsider.com. The titles are as follows: “Benzinga’s Daily Biotech Pulse: Eli Lilly, Edge Therapeutics, BioXcel Report Positive Trial Results, 4 Stocks Debut” posted on June 28, 2018, “Acasti Pharma Business Update for the Fourth Quarter and Fiscal 2018” on June 27, 2018, “Acasti Pharma to Present at the XVIII(th) International Symposium on Atherosclerosis” with a publish date: June 06, 2018, “Acasti Pharma Appoints Brian Groch as Chief Commercial Officer” and the last “Form 6-K Acasti Pharma Inc. For: Jun 04” with publication date: June 05, 2018.

Acasti Pharma Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of prescription drugs for the treatment of cardiovascular diseases.The company has $25.26 million market cap. The company's lead product candidate is CaPre, an omega-3 phospholipid for the treatment of hypertriglyceridemia.Currently it has negative earnings.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.